Medically Reviewed Content
Written by Rob Anderson, Health Technology Researcher & Medical Content Specialist. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting any medication.
Two molecules dominate the GLP-1 weight loss landscape in 2026: semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound). If you are trying to decide between them — or trying to access one affordably — here is everything you need to know.
The Core Difference: Mechanism of Action
Semaglutide is a GLP-1 receptor agonist. It mimics the GLP-1 hormone to suppress appetite, slow gastric emptying, and improve blood sugar regulation.
Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both the GLP-1 receptor AND the GIP (glucose-dependent insulinotropic polypeptide) receptor. This dual action is why tirzepatide tends to produce greater weight loss: you get the combined appetite-suppressing and metabolic effects of two hormonal pathways instead of one.
Weight Loss Results: Head-to-Head
| Drug | Avg. Weight Loss (72 weeks) | Max Dose | Injection Frequency |
|---|---|---|---|
| Semaglutide (Wegovy) | ~15% body weight | 2.4mg weekly | Weekly |
| Tirzepatide (Zepbound) | ~22% body weight | 15mg weekly | Weekly |
| Compounded Semaglutide | Similar to Wegovy | Varies | Weekly |
Side Effects: How Do They Compare?
Both drugs share similar side effect profiles since they both activate GLP-1 receptors. The most common side effects for both are nausea, vomiting, diarrhea, and constipation — especially during dose escalation. These tend to be worse in the first few weeks and improve over time. Tirzepatide’s additional GIP action does not appear to meaningfully increase the rate of these side effects compared to semaglutide.
Cost Comparison in 2026
| Option | Monthly Cost (No Insurance) | Insurance Coverage |
|---|---|---|
| Wegovy (brand) | $1,000–$1,400 | Varies — obesity coverage improving |
| Zepbound (brand) | $900–$1,100 | Varies |
| Compounded Semaglutide ✓ | $149–$299 | No insurance needed |
Key insight: While tirzepatide produces better weight loss results on paper, many people cannot access it without insurance. Compounded semaglutide — available without insurance for $149–$299/month — makes semaglutide the far more accessible option for most people in 2026. For more details, see our estimate your expected weight loss.
Tirzepatide 2026 Update: Latest News & Clinical Data
Tirzepatide had a landmark year in 2025–2026. Here’s what’s new:
- Zepbound approved for sleep apnea (2024): The FDA approved tirzepatide (Zepbound) for moderate-to-severe obstructive sleep apnea in adults with obesity — the first weight loss drug approved for this indication.
- SURMOUNT-OSA trial: Tirzepatide reduced sleep apnea events by up to 63% in clinical trials, compared to placebo.
- Tirzepatide for heart failure: The SUMMIT trial showed tirzepatide significantly improved symptoms and exercise capacity in patients with heart failure with preserved ejection fraction (HFpEF).
- Compounded tirzepatide ban (2025): FDA removed tirzepatide from its drug shortage list in mid-2025, ending legal 503B compounding. Brand-name Mounjaro/Zepbound are now the only legal sources.
- Orforglipron (oral GIP/GLP-1): Eli Lilly’s oral tirzepatide-class drug is in late-stage trials — potential game-changer for needle-free GLP-1 in 2026–2027.
Semaglutide vs Tirzepatide: Full 2026 Comparison
| Factor | Semaglutide (Ozempic/Wegovy) | Tirzepatide (Mounjaro/Zepbound) |
|---|---|---|
| Drug Class | GLP-1 receptor agonist | Dual GIP + GLP-1 agonist |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Weight Loss (avg) | ~15–17% (Wegovy 2.4mg) | ~20–22% (Zepbound 15mg) |
| A1C Reduction | ~1.5–1.8% | ~2.0–2.3% |
| Dosing | Once weekly injection | Once weekly injection |
| Max Dose | 2.4 mg (Wegovy) / 2 mg (Ozempic) | 15 mg (Zepbound/Mounjaro) |
| Cardiovascular Benefit | SELECT trial: 20% CV event reduction | SURPASS-CVOT ongoing |
| Sleep Apnea Approval | No | Yes (Zepbound, 2024) |
| Monthly List Price | ~$1,349 (Wegovy) / ~$968 (Ozempic) | ~$1,059 (Zepbound) / ~$1,069 (Mounjaro) |
| Insurance Coverage | Broader (Ozempic for T2D) | Growing (Zepbound for obesity) |
Which Drug Wins for Weight Loss?
In head-to-head comparisons, tirzepatide consistently outperforms semaglutide for weight loss. The SURMOUNT-5 trial (2024) directly compared Zepbound vs Wegovy — tirzepatide users lost 47% more body weight on average (20.2% vs 13.7%). For more details, see our Ozempic vs Zepbound comparison.
However, semaglutide has advantages in specific areas:
- Proven cardiovascular benefit — SELECT trial confirmed 20% reduction in major cardiac events in non-diabetic obese patients
- Longer track record — more real-world safety data accumulated
- Better insurance coverage — Ozempic for diabetes is widely covered; Wegovy coverage has expanded with the SELECT data
- Generic semaglutide on the horizon — Novo Nordisk’s patents begin expiring after 2026
Who Each Drug Is Best For
Choose Semaglutide (Ozempic/Wegovy) if:
- You have cardiovascular disease or high CV risk
- Your insurance covers it but not tirzepatide
- You want the drug with the most long-term safety data
- You’re managing Type 2 diabetes primarily (Ozempic)
Choose Tirzepatide (Mounjaro/Zepbound) if:
- Maximum weight loss is your primary goal
- You also have sleep apnea alongside obesity
- You have Type 2 diabetes with difficult-to-control blood sugar (stronger A1C reduction)
- You haven’t responded well to semaglutide
Frequently Asked Questions
Can you switch from semaglutide to tirzepatide?
Yes — switching is relatively common, especially when patients plateau on semaglutide or want better weight loss results. Typically, doctors restart from the lowest tirzepatide dose (2.5 mg) with a wash-in period of 1–2 weeks after stopping semaglutide.
Is tirzepatide available as a generic in 2026?
No. Tirzepatide is still under patent protection. Eli Lilly’s patents on Mounjaro/Zepbound extend well into the 2030s, so no generic is expected soon. The FDA also removed tirzepatide from the drug shortage list in 2025, ending the window for compounded versions.
Which has worse side effects — semaglutide or tirzepatide?
Both have similar GI side effect profiles (nausea, vomiting, diarrhea, constipation). Tirzepatide may have slightly higher rates of nausea in early titration due to its dual GIP/GLP-1 mechanism, but this typically resolves within weeks. Neither drug’s side effects are dramatically worse than the other.
📚 Related Reading
📖 Further Reading
Access Compounded Semaglutide From $149/Month
No insurance needed. See if you qualify in 60 seconds.
Sponsored | Affiliate link | Not available in all states
Which Should You Ask For?
If maximum weight loss is your primary goal and you have insurance coverage or can afford brand-name pricing, tirzepatide (Zepbound) has the stronger clinical data. If accessibility and affordability are priorities — or if you do not have insurance — compounded semaglutide is the pragmatic choice. It delivers meaningful, clinically significant weight loss at a price point that makes long-term adherence realistic.
This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any medication.
Sources & References
- U.S. Food and Drug Administration (FDA) – Drug Approvals and Databases
- National Institutes of Health (NIH) – PubMed Medical Literature
- American Diabetes Association – Medication & Therapies
- Novo Nordisk – Clinical Research Data
- Eli Lilly – Medical Information
This content is regularly reviewed and updated to reflect the latest medical research and FDA guidance.